Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Cermin Dunia Kedokteran Cermin Dunia Kedokteran
Wibisono Nugraha
Departemen Ilmu Kesehatan Kulit dan Kelamin, RSUD dr. Moewardi/Fakultas Kedokteran Univesitas Sebelas Maret, Surakarta, Indonesia
Health Professions Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Terapi Kortikosteroid Sistemik untuk Sindrom Steven Johnson (SSJ)- Nekrolisis Epidermal Toksik (NET) di RSUD DR Moewardi, Surakarta, Indonesia Eka Devinta; Novi Diana; Rakhma Tri Irfanti; Alfina Rahma; Frieda; Wibisono Nugraha; Muhammad Eko Irawanto
Cermin Dunia Kedokteran Vol 48 No 4 (2021): Dermatologi
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v48i4.60

Abstract

Latar belakang :Sindrom Steven Johnson (SSJ) dan nekrolisis epidermal toksik (NET) adalah manifestasi reaksi alergi obat paling berat dan mengancam jiwa yang dimediasi sel T. Salah satu terapi SSJ-NET yaitu kortikosteroid sistemik. Tujuan : Mengetahui pola terapi kortikosteroid sistemik di Instalasi Rawat Inap RSUD Dr. Moewardi Surakarta periode Januari 2014-Desember 2018. Metode : Penelitian deskriptif retrospektif atas data rekam medis pasien SSJ-NET di Instalasi Rawat Inap RSUD Dr. Moewardi Surakarta periode Januari 2014-Desember 2018. Hasil: Didapatkan 80 pasien SSJ-NET, usia terbanyak 46-65 tahun (39%), lebih banyak laki-laki (52%). Diagnosis SSJ paling banyak (61%) dibandingkan SSJ overlap NET (24%) ataupun NET (15%) dengan keterlibatan mukosa mulut terbanyak (64%). Penyakit penyerta terbanyak adalah diabetes melitus (18 %). Penyebab SSJ-NET terbanyak diduga lebih dari satu obat (44%). Terapi kortikosteroid sistemik berupa injeksi metilprednisolon dengan rata-rata dosis 65 mg/hari dan lama perawatan 10 hari. Simpulan: Kortikosteroid sistemik merupakan terapi semua kasus SSJ-NET di RSUD dr. Moewardi Surakarta. Background: Steven Johnson syndrome (SSJ) and toxic epidermal necrolysis (TEN) are the severest primarily T-cell mediated manifestation and life threatening drug reaction. Systemic corticosteroid is used for SSJ-TEN management. Objective: To study the pattern of systemic corticosteroid therapy for SSJ-TEN in Dr. Moewardi General Hospital Surakarta Januari 2014-December 2018. Method: A descriptive retrospective study on medical record data of SSJ-TEN patients hospitalized at Dr. Moewardi General Hospital Surakarta between January 2014 and December 2018. Results: From a total 80 SSJ–TEN patients in this study, 39% was 46-65 year-old, male (52%). The most frequent diagnosis was SSJ (61%) followed by SSJ overlap TEN (24%) and TEN (15%), mostly with mucosal mouth involvement (64%). The most frequent comorbidities were DM (18%). More than one drug was related to SSJ-TEN (44%). Therapy for all cases was systemic corticosteroids with an average dose of methylprednisolone 65 mg per day in 10 days. Conclusion: Systemic corticosteroids were used in all cases of SSJ-NET in Dr. Moewardi General Hospital Surakarta.
Terapi Kortikosteroid Sistemik untuk Sindrom Steven Johnson (SSJ)- Nekrolisis Epidermal Toksik (NET) di RSUD DR Moewardi, Surakarta, Indonesia Eka Devinta; Novi Diana; Rakhma Tri Irfanti; Alfina Rahma; Frieda; Wibisono Nugraha; Muhammad Eko Irawanto
Cermin Dunia Kedokteran Vol 48 No 4 (2021): Dermatologi
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v48i4.60

Abstract

Latar belakang :Sindrom Steven Johnson (SSJ) dan nekrolisis epidermal toksik (NET) adalah manifestasi reaksi alergi obat paling berat dan mengancam jiwa yang dimediasi sel T. Salah satu terapi SSJ-NET yaitu kortikosteroid sistemik. Tujuan : Mengetahui pola terapi kortikosteroid sistemik di Instalasi Rawat Inap RSUD Dr. Moewardi Surakarta periode Januari 2014-Desember 2018. Metode : Penelitian deskriptif retrospektif atas data rekam medis pasien SSJ-NET di Instalasi Rawat Inap RSUD Dr. Moewardi Surakarta periode Januari 2014-Desember 2018. Hasil: Didapatkan 80 pasien SSJ-NET, usia terbanyak 46-65 tahun (39%), lebih banyak laki-laki (52%). Diagnosis SSJ paling banyak (61%) dibandingkan SSJ overlap NET (24%) ataupun NET (15%) dengan keterlibatan mukosa mulut terbanyak (64%). Penyakit penyerta terbanyak adalah diabetes melitus (18 %). Penyebab SSJ-NET terbanyak diduga lebih dari satu obat (44%). Terapi kortikosteroid sistemik berupa injeksi metilprednisolon dengan rata-rata dosis 65 mg/hari dan lama perawatan 10 hari. Simpulan: Kortikosteroid sistemik merupakan terapi semua kasus SSJ-NET di RSUD dr. Moewardi Surakarta. Background: Steven Johnson syndrome (SSJ) and toxic epidermal necrolysis (TEN) are the severest primarily T-cell mediated manifestation and life threatening drug reaction. Systemic corticosteroid is used for SSJ-TEN management. Objective: To study the pattern of systemic corticosteroid therapy for SSJ-TEN in Dr. Moewardi General Hospital Surakarta Januari 2014-December 2018. Method: A descriptive retrospective study on medical record data of SSJ-TEN patients hospitalized at Dr. Moewardi General Hospital Surakarta between January 2014 and December 2018. Results: From a total 80 SSJ–TEN patients in this study, 39% was 46-65 year-old, male (52%). The most frequent diagnosis was SSJ (61%) followed by SSJ overlap TEN (24%) and TEN (15%), mostly with mucosal mouth involvement (64%). The most frequent comorbidities were DM (18%). More than one drug was related to SSJ-TEN (44%). Therapy for all cases was systemic corticosteroids with an average dose of methylprednisolone 65 mg per day in 10 days. Conclusion: Systemic corticosteroids were used in all cases of SSJ-NET in Dr. Moewardi General Hospital Surakarta.
Co-Authors Alfina Rahma Eka Devinta Frieda Muhammad Eko Irawanto Novi Diana Rakhma Tri Irfanti